Literature DB >> 25317790

NT-proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus.

Y-J Ding1, B Han, B Yang, M Zhu.   

Abstract

OBJECTIVE: The aim of this study was to clarify the role of N-terminal pro-brain natriuretic peptide, (NT-proBNP) in ibuprofen on preterm infants with patent ductus arteriosus (PDA). PATIENTS AND METHODS: Preterm infants with PDA were enrolled in the present study. Patients were randomized into two groups: ibuprofen group received oral ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 h, and the placebo group received the same volume of 5% glucose. PDA and NT-proBNP were detected during 24 hours, 3 and 7 days of age.
RESULTS: The results indicated that babies who received oral ibuprofen had higher PDA closure at 7 days after treatment (p < 0.05). Significantly decrease of NT-proBNP was found in ibuprofen group than the placebo group at 3 and 7 days (all p < 0.05).
CONCLUSIONS: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25317790

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN： 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Souvik Mitra; Ivan D Florez; Maria E Tamayo; Lawrence Mbuagbaw; Thuva Vanniyasingam; Areti Angeliki Veroniki; Adriana M Zea; Yuan Zhang; Behnam Sadeghirad; Lehana Thabane
Journal:  JAMA       Date:  2018-03-27       Impact factor: 56.272

2.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

Review 3.  Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment?

Authors:  Meera N Sankar; William E Benitz
Journal:  J Perinatol       Date:  2020-10-06       Impact factor: 2.521

Review 4.  Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.

Authors:  Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2018-09-28

5.  Predictive Value of Blood N-Terminal Pro-Brain Natriuretic Peptide Concentrations for Early Patent Ductus Closure in Very Preterm Infants.

Authors:  Solomiia Potsiurko; Dmytro Dobryanskyy; Lesya Sekretar
Journal:  J Saudi Heart Assoc       Date:  2021-01-08

6.  Factors Associated With Benefit of Treatment of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.

Authors:  Esther J S Jansen; Tim Hundscheid; Wes Onland; Elisabeth M W Kooi; Peter Andriessen; Willem P de Boode
Journal:  Front Pediatr       Date:  2021-02-09       Impact factor: 3.418

7.  Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?

Authors:  Ya-Lan Lin; Yi-Li Hung; Chung-Min Shen; Yung-Chuan Chen; Wu-Shiun Hsieh
Journal:  Children (Basel)       Date:  2022-07-03

8.  Clinical significance of plasma levels of brain natriuretic peptide and cardiac troponin T in patients with sepsis.

Authors:  Jifeng Wang; Wenli Ji; Zhengqin Xu; Tao Pan
Journal:  Exp Ther Med       Date:  2015-11-12       Impact factor: 2.447
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.